# $ocgn

Ocugen's OCU400 Phase [--] trial for RP is reportedly progressing, with discussions around enrollment and trial structure. Meanwhile, concerns about financial risks and clinical efficacy for OCU410 persist among social media users.

### About $ocgn
Ocugen is a biotechnology company focused on developing novel therapeutics, particularly gene therapies for retinal diseases.  

### Engagements: [-----] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$ocgn/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$ocgn/time-series/interactions.tsv)  
Current Value: [-----]  
Daily Average: [------]  
[--] Week: [---] -82%  
[--] Month: [-------] -37%  
[--] Months: [---------] -41%  
[--] Year: [---------] -63%  
1-Year High: [-------] on 2025-03-05  
1-Year Low: [-----] on 2025-12-08  

Engagements by network (24h):
X: [-----]
Reddit: [--]
TikTok: [--]
YouTube: [--]

  
  
### Mentions: [---] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$ocgn/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$ocgn/time-series/posts_active.tsv)  
Current Value: [---]  
Daily Average: [---]  
[--] Months: [--] +3,650%  
1-Year High: [---] on 2025-06-30  
1-Year Low: [--] on 2025-12-08  

Mentions by network (24h):
X: [---]
Reddit: [--]
TikTok: [--]
YouTube: [--]

  
  
### Creators: [--] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$ocgn/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$ocgn/time-series/contributors_active.tsv)  
[--] unique social accounts have posts mentioning $ocgn in the last [--] hours which is up 62% from [--] in the previous [--] hours
Daily Average: [--]  
[--] Months: [--] +1,900%  
1-Year High: [---] on 2025-06-30  
1-Year Low: [--] on 2025-09-07  

The most influential creators that mention $ocgn in the last [--] hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@MoreFlax](/creator/twitter/MoreFlax)               | [--]    | [-----]     | [--]    | [-----]       |
| [@AmeliaVilla](/creator/twitter/AmeliaVilla)         | [--]    | [--]         | [--]    | [---]         |
| [@GuzmanAlic16045](/creator/twitter/GuzmanAlic16045) | [--]    | [--]        | [--]     | [---]         |
| [@Iam__Mouni](/creator/twitter/Iam__Mouni)           | [--]    | [---]       | [--]    | [---]         |
| [@anita37992698](/creator/twitter/anita37992698)     | [--]    | [---]       | [--]    | [---]         |
| [@LucyTrader98](/creator/twitter/LucyTrader98)       | [--]    | [---]       | [--]     | [---]         |
| [@NattaCop](/creator/twitter/NattaCop)               | [--]    | [-----]     | [--]     | [---]         |
| [@LilyTrader10](/creator/twitter/LilyTrader10)       | [--]    | [--]         | [--]     | [---]         |
| [@amazing_stocks](/creator/twitter/amazing_stocks)   | [--]    | [---]       | [--]     | [---]         |
| [@SeanValenc89161](/creator/twitter/SeanValenc89161) | [--]   | [---]       | [--]     | [--]          |

[View More](/list/creators/$ocgn/100)
  
  
### Sentiment: 57%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$ocgn/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$ocgn/time-series/sentiment.tsv)  
Current Value: 57%  
Daily Average: 89%  
[--] Week: 43% -57%  
[--] Month: 51% -19%  
[--] Months: 51% -49%  
[--] Year: 51% -49%  
1-Year High: 100% on 2025-02-17  
1-Year Low: 29% on 2025-12-13  

Most Supportive Themes:
- Discord Communities: (60%) Several posts are promoting Discord communities, often associated with trading or investment groups. These communities appear to be a significant hub for discussion and potential signal sharing.
- Stock Market Discussion: (30%) Posts frequently mention stock tickers alongside $OCGN, indicating a focus on its performance within the broader stock market and investment landscape.
  
Most Critical Themes:
- Financial Risk and Dilution: (70%) One post highlights significant financial risks, including a high monthly burn rate and the likelihood of future dilution, questioning whether potential catalysts outweigh these financing concerns.
- Clinical Trial Progress: (30%) While mentioning clinical trial timelines (rolling BLA for H1 2026, pivotal data for Q4 2026), there's an underlying concern about the efficacy signals and dose-selection questions for OCU410.
  

### Top $ocgn Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"📊 Trade smarter join our Discord Discord Link Here ➡ $INTC $MU $PYPL $MARA $OCGN https://discord.gg/b8Y2US8J3z https://discord.gg/b8Y2US8J3z"  
[X Link](https://x.com/amazing_stocks/status/2022876017929474250) [@amazing_stocks](/creator/x/amazing_stocks) 2026-02-15T03:30Z [---] followers, [---] engagements


"$NWGL cup and handle on chart. $1.34 with vol surge eco hype driving positives $CHEK $STOK $OPGN $CISS $MESO $OCGN $DNUT $SWIN $DJT $PHUN $BTC $ETH $DOGE $AMC $SPY $BETSF $HOLO $BCAN $STI $NVDA $ICU $TSLA $RDDT $MLGO $SOXS $ANTE $NUVB $HOOD $QH $NBSE $AMPE $VMEO $AEHR $TIRX"  
[X Link](https://x.com/LucyTrader98/status/2022798485502701934) [@LucyTrader98](/creator/x/LucyTrader98) 2026-02-14T22:21Z [---] followers, [---] engagements


"$OCGN #OCUGEN @Ocugen @drsmusunuri @drhumaqamar This is a game changer https://www.breitbart.com/politics/2026/02/12/exclusive-howard-lutnick-400-billion-of-pharma-manufacturing-coming-home-to-america/ https://www.breitbart.com/politics/2026/02/12/exclusive-howard-lutnick-400-billion-of-pharma-manufacturing-coming-home-to-america/"  
[X Link](https://x.com/MoreFlax/status/2022501466704085424) [@MoreFlax](/creator/x/MoreFlax) 2026-02-14T02:41Z [----] followers, [----] engagements


"$ocgn Hey fam. 👨🌾 Unsure confused curious If so listen to what Im about to say closely because Im about to disclose something that only someone whos followed this company for years would catch. Ocugens OCU400 Phase [--] for RP started dosing in June [----]. The narrative youll hear from practically everyone is that the trial is still not fully enrolled. And sure thats half true. But people are so hung up on active enrollment that they completely miss how the trial is built. Phase [--] is two arms. One arm is [--] patients with RP caused by the RHO gene. The other arm is [--] patients with broad RP."  
[X Link](https://x.com/NattaCop/status/2021040473591492826) [@NattaCop](/creator/x/NattaCop) 2026-02-10T01:56Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing